Targeted drug trial offers hope for Tough-to-Treat melanoma
NCT ID NCT03420508
Summary
This study is testing whether the drug ensartinib can help control advanced melanoma that has specific genetic changes in the ALK gene. The trial is for patients whose cancer has continued to grow despite standard treatments like immunotherapy. Researchers want to see if this targeted drug can shrink tumors or stop their growth for at least 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.